Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion
Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This study will be an open-label, cross-over study as subjects will be studied under both
study conditions - suspension of subcutaneous insulin infusion via pump during treatment with
insulin alone (control) vs. suspension of subcutaneous insulin via pump during treatment with
insulin and canagliflozin.
Phase:
N/A
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)